CMS has announced that Phase I of the MHS disease management demonstration program will end after three years of operation. Preliminary evaluations have found that the program is not meeting the statutory requirements of improved clinical quality outcomes, improved beneficiary satisfaction, and the achievement of financial savings targets. CMS will determine whether to implement Phase II of the program depending on the results of further independent evaluations.